Overview

An Open Study Assessing the Safety and Tolerability of U3-1784

Status:
Terminated
Trial end date:
2017-02-28
Target enrollment:
Participant gender:
Summary
The main objectives of the trial are: - To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours - To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.